Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

CNBC June 30, 2025
Annika Kim Constantino

Key Points

– Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial.

– The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.

– The results also clear a path forward for Moderna’s combination jab targeting Covid-19 and influenza after the company voluntarily withdrew its application for U.S. approval of that shot.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and Covid jab.

Moderna in...

Today's Sponsors

Today's Sponsor